Abstract
In 2006, the circulating influenza A virus rapidly became resistant to the adamantanes, prompting recommendations against their use and leaving only neuraminidase inhibitors (NAIs; e.g., oseltamivir, zanamivir) for treatment or prophylaxis. To assess the prevalence of resistance to NAIs, CDC investigators conducted a surveillance study of influenza A virus (H1N1). For …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
